GlassScriptPhysician profile
Nikhil A Daga
NPI 1487811212
$23,216.46
in general payments reported to CMS, 2019-2025
55 companies · $3,005 in 2025
The $3,005 reported for 2025 was more than what 75% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,596 · 2020: $1,016 · 2021: $6,398 · 2022: $3,492 · 2023: $2,963 · 2024: $3,746 · 2025: $3,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,396 · Travel and Lodging: $270 · Entertainment: $48.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,396.22 |
| Travel and Lodging | $269.52 |
| Entertainment | $48.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $6,787.36 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Abbott Laboratories | $2,690.25 | 2019-2025 | Dragonfly Opstar, Xience V, Optis |
| Boston Scientific Corporation | $2,118.93 | 2019-2025 | Watchman Flx, Sentinel, Watchman Access System |
| Novartis Pharmaceuticals Corporation | $1,926.18 | 2019-2025 | |
| Amgen INC. | $1,181.19 | 2019-2025 | Repatha, Repatha |
| Inari Medical, INC. | $946.57 | 2021-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pfizer INC. | $860.83 | 2019-2025 | |
| Shockwave Medical, INC | $768.73 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $619.72 | 2019-2025 | Lifevest |
| Cardiva Medical, INC. | $481.12 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f, Cardiva Vascade 6/7f Vcs |
| Janssen Pharmaceuticals, INC | $395.58 | 2019-2022 | |
| Abiomed | $370.43 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $326.10 | 2019-2025 | Camzyos |
| Actelion Pharmaceuticals US, INC. | $324.27 | 2021-2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $309.06 | 2021-2025 | Verquvo, Capvaxive |
Show all 52 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Daga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.